SELLAS Life Sciences
31 hedge funds and large institutions have $3.72M invested in SELLAS Life Sciences in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 5 closing their positions.
5,170% more call options, than puts
Call options by funds: $2.63M | Put options by funds: $50K
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
11% more funds holding
Funds holding: 28 → 31 (+3)
1.2% more ownership
Funds ownership: 9.76% → 10.96% (+1.2%)
18% less capital invested
Capital invested by funds: $4.54M → $3.72M (-$815K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$887K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$202K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$119K |
| 4 |
OCG
Opus Capital Group
Cincinnati,
Ohio
|
+$109K |
| 5 |
Bank of New York Mellon
New York
|
+$69.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$693K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$76.2K |
| 3 |
PFG
Prosperity Financial Group
San Ramon,
California
|
-$40.7K |
| 4 |
Jane Street
New York
|
-$18.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.96K |
SLS Hedge Fund Activity: Q4 2023 in Review
31 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q4 2023, worth a combined $3.72M — down 18% from $4.54M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SLS positions and 5 closed out — a net gain of 3 holders — while 12 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $887K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $693K sold.
- 31 institutional investors held SELLAS Life Sciences (SLS) as of Q4 2023, up from 28 in Q3 2023.
- Funds reported $3.72M of SELLAS Life Sciences stock for Q4 2023, down 18% quarter-over-quarter.
- 8 funds opened new SELLAS Life Sciences positions in Q4 2023 and 5 closed out, a net change of +3 holders.
- The largest SELLAS Life Sciences buyer in Q4 2023 was Armistice Capital, an estimated $887K added.
- The largest SELLAS Life Sciences seller in Q4 2023 was Alyeska Investment Group, an estimated $693K sold.
Based on aggregated 13F filings for Q4 2023.